平安好醫生(01833.HK)推醫藥新零售戰略產品「藥診付」
平安好醫生(01833.HK)宣布,計劃融合商業保險打造醫藥新零售模式,推出創新戰略產品「藥診付」,以在線醫療服務為核心,為藥店和藥企提供服務、實物、保險、系統與數據四大產品,解決用戶診療、購藥及支付三大問題。
主席兼首席執行官方蔚豪透露,藥診付建立原研藥、進口藥等藥品商保目錄,滿足患者用藥需求,目前覆蓋全國近30個省級行政區,近300個地級市,打通近千家連鎖藥房及5萬家藥店。
他又指,平安好醫生通過打通自建大倉、中心倉、O2O等網絡渠道,建立線上線下綜合生態圈,藥店雲問診合作藥店數目已達15.1萬家,覆蓋全國32個省級行政區、379個城市,並與超過4,000家連鎖藥店品牌展開合作,與近千家藥企建立供應鏈合作,其供應鏈品種超過6,000種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.